Objective The effects of fasudil on refractory pulmonary arterial hypertension after surgery for ventricular septal defect. Objective To evaluate the therapeutic effects of fasudil on refractory pulmonary arterial hypertension(PAH) after surgery for ventricular septal defect. Methods Seventeen ventricular septal defect patients with postoperational refractory PAH after surgery for ventricular septal defect were randomly divided into control group (n=9, 2 months of normal saline inhalation plus conventional therapy) and treatment group (n=8, 12 months of fasudil inhalation plus conventional therapy). The PASP, RVEF, and LVEF were measured by echocardiography before and 3, 6, and 12 months after the treatment. PaO2 was monitored. Results Cumulative survival rate in the control group were 87.5% at 3 years and 62.5% at 5 years, while that in the treatment group was 100% at 5 years. Compared with the control group, PASP of patients in the treatment group decreased significantly at 6 and 12 months after fasudil treatment(P<0.01), LVEF and PaO2 of patients in the treatment group increased significantly at 6 and 12 months(P<0.01); while RVEF of patients in the treatment group showed significant increase at 3 months(P<0.05) and continued to increase at 6 and 12 months(P<0.01). Conclusions Fasudil inhalation therapy after corrective surgery for ventricular septal defect was associated with a reduction in pulmonary arterial systolic pressure,increase of heart function and lower risk of death.
NETL
NSTL
万方数据
维普
